In the earlier mentioned product program, co-treatment with UIC2 + CsA potentiated the anti-tumor impact of DOX and inhibited or hindered the advancement of KB-V1 Pgp+ tumors in vivo (Fig. 4)
Fig. six shows the A-804598 result of human peripheral blood mononuclear cells (PBMCs), and of human serum samples, on UIC2 mAb dealt with KB-V1 and KB-3-one cells, in vitro. PBMCs…